AffDC5 Jul 2024 21:43
AffDC – “The peptide-warhead conjugate is linked to a tumour antigen-targeted monoclonal antibody [mAb] or Affimer, creating a highly tumor-specific ADC”.
Some of these mAb-based therapies are very effective – once they reach the TME, just that there can be some rather unpleasant side-effects on the way.
What if these therapies could be delivered directly to the TME, where they are ‘dropped off’ to do their work, with minimal damage to healthy tissue? Enter AffDC.
Examples (just 3 selected, from a lot more) ..?
Herceptin (Trastuzumab), Company: Roche/Genentech, Patent Expiry: US: June 18, 2019; EU: July 28, 2014, Annual Revenue: ~$6.9 billion (2018), Biological Target: HER2 (human epidermal growth factor receptor 2), Cancers Treated: HER2-positive breast cancer ( FAPα Expression: Moderate to high in cancer-associated fibroblasts), HER2-positive gastric cancer (FAPα Expression: High in stromal fibroblasts).
Avastin (Bevacizumab), Company: Roche/Genentech, Patent Expiry: US: July 18, 2019; EU: January 8, 2022, Annual Revenue: ~$7 billion (2018), Biological Target: VEGF (vascular endothelial growth factor), Cancers Treated: Colorectal cancer (FAPα Expression: High in stromal fibroblasts), non-small cell lung cancer (FAPα Expression: High in stromal fibroblasts), glioblastoma (FAPα Expression: High in tumor stroma), , renal cell carcinoma (FAPα Expression: Moderate to high in stromal fibroblasts), , cervical cancer (FAPα Expression: High in stromal fibroblasts).
Keytruda (Pembrolizumab), Company: Merck & Co., Patent Expiry: US: January 18, 2028; EU: August 21, 2028, Annual Revenue: ~$14.4 billion (2020), Biological Target: PD-1 (programmed death-1). Cancers Treated: Melanoma (FAPα Expression: Moderate to high in tumor stroma), non-small cell lung cancer, head and neck squamous cell carcinoma (FAPα Expression: High in stromal fibroblasts), classical Hodgkin lymphoma (FAPα Expression: Moderate in the tumor microenvironment), urothelial carcinoma (FAPα Expression: Moderate to high in stromal fibroblasts), , microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers (FAPα Expression: High in the tumor microenvironment).
(Research AssIstant – ChatGPT 4.o – quite a lot of questions asked – please DYOR).
I think AffDC could be quite ‘big’ (maybe even ‘really ‘big’)? Roll on pipeline reveal.
GLA
Sign In
Follow the stocks
